Results 191 to 200 of about 5,547 (244)

Multiple Switches Between Adalimumab-fkjp and Reference Adalimumab in Moderate-to-Severe Chronic Plaque Psoriasis: A Multicenter, Double-Blind, Parallel Group, Randomized Clinical Trial for Interchangeability. [PDF]

Adv Ther
Deodhar S, Loganathan S, Kadadanamari Subbarama Reddy R, Ranganna GM, Liu S, Hummel MA, Daniluk S, Hanczewska A, Vekovska K, Zegadlo-Mylik M, Pulka G, -Holz EW.   +11 more
europepmc   +1 more source

Medicare spending and use of subcutaneous biologic formulations with hyaluronidase. [PDF]

Oncologist
Kim J, Kesselheim AS, Cliff ERS, Rome BN.   +3 more
europepmc   +1 more source

The consequences of pharmaceutical tariffs in the United States. [PDF]

J Manag Care Spec Pharm
Sullivan SD, Grueger J, Sullivan AP, Ramsey SD.   +3 more
europepmc   +1 more source

Regulierung und adäquate Preisbildung im Markt der Biosimilars: Projekt im Auftrag der Pfizer Deutschland GmbH

, 2017
Altin, Sibel, Bauer, Cosima, May, Uwe, Walendzik, Anke, Wasem, Jürgen, Ziebe, Anissa   +5 more
core  

Mesenchymal stromal cells as rescue therapy in biologic-refractory psoriasis: insights from a case series. [PDF]

Front Immunol
Lwin SM, Solanky S, Scottà C, Giacomini C, Azrielant S, Tosi I, Al-Haddabi A, Duarte-Williamson E, Dawe H, Walsh S, McGrath JA, Lombardi G, Dazzi F, Di Meglio P, Griffiths CEM.   +14 more
europepmc   +1 more source

Efficacy and safety of insulin degludec/insulin aspart biosimilar B01711 vs originator insulin degludec/insulin aspart in Chinese patients with type 2 diabetes inadequately controlled on basal or premixed insulin: A multicenter, randomized, open-label, phase 3 study. [PDF]

J Diabetes Investig
Gao L, Cheng Z, Ma G, Cai X, Wang X, Lu Y, Li Z, Li W, Zhao S, Li X, Song C, Gao Y, Geng J, Cao H, Sun J, Ji L.   +15 more
europepmc   +1 more source

Summary of Research: Immunogenicity of Adalimumab Reference Product and Adalimumab-adbm in Patients with Rheumatoid Arthritis, Crohn's Disease, and Chronic Plaque Psoriasis: A Pooled Analysis of the VOLTAIRE trials. [PDF]

Rheumatol Ther
Strand V.
europepmc   +1 more source

Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study. [PDF]

Acta Derm Venereol
Sieborg J, Maul JT, Wu JJ, Loft NN, Skov L, Bryld LE, Rasmussen MK, Dam TN, Bertelsen T, Ajgeiy KK, Thomsen SF, Thyssen JP, Egeberg A, Thein D.   +13 more
europepmc   +1 more source

Perceptions and Preferences for Defining Biosimilar Products in Prescription Drug Promotion. [PDF]

J Am Board Fam Med
Johnson M, Thompson JE, Tilley AA, O'Donoghue AC, Aikin KJ.   +4 more
europepmc   +1 more source

Risk management in the distribution process of biosimilar products in the pharmaceutical industry

, 2016
openaire   +1 more source